focus -WSS

focus

author：comprehensive 2025-10-01 14:19:00 - browse：57

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： CMS should re

leisure time

hotspot

entertainment

WSS

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

CMS should re

What the cancer research community can learn from the Covid response

FDA approves world's first CRISPR

Dramatically reducing cancer deaths requires the PASTEUR Act

focus

focus

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

TytoCare raises $49 million to build out AI

Moonlake's readout produced a cash windfall. Risks remain

FDA needs staff influx to meet gene therapy needs, Marks says

Alkermes shareholders re

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Trump demands the U.S. pay no more for drugs than other countries … again

CMS should re

Affirmative action in medical school literally saved lives

After sickle

knowledge

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Dramatically reducing cancer deaths requires the PASTEUR Act

Chemotherapy shortages won’t get better under Biden’s latest plan

Patients' immediate access to test results puts radiologists in a bind

ER docs worry over extreme heat as a 'mass casualty event'

Dramatically reducing cancer deaths requires the PASTEUR Act

hotspot

entertainment

entertainment

knowledge